Dogwood Therapeutics (DWTX) Research & Development (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Research & Development of $2.7 million for Q1 2026, up 9.55% year-over-year from $2.4 million in Q1 2025, and up 14.2% quarter-over-quarter from $2.3 million in Q4 2025.
Dogwood Therapeutics (DWTX) Research & Development (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Research & Development for 7 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 9.55% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $22.1 million (up 292.92% YoY), while the FY2025 annual figure was $21.9 million, up 519.28% from the prior year.
- Research & Development advanced to $2.7 million in Q1 2026 per DWTX's latest filing, from $2.3 million in the prior quarter.
- Across five years, Research & Development topped out at $14.5 million in Q3 2025 and bottomed at $298321.0 in Q4 2023.
- Historically, Research & Development has averaged $2.2 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development sank 82.03% — and 2025, when it surged 2613.45%.
- Dogwood Therapeutics' Research & Development stood at $1.3 million in 2022, then slumped by 76.54% to $298321.0 in 2023, then surged by 676.33% to $2.3 million in 2024, then increased by 0.94% to $2.3 million in 2025, then climbed by 14.2% to $2.7 million in 2026.
- Business Quant data shows DWTX's Research & Development at $2.7 million in Q1 2026, $2.3 million in Q4 2025, and $14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 97.90 Mn |
| 10 | Dogwood Therapeutics | 82.25 Mn | 82.25 Mn | - | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.67 Mn |
| Dec 31, 2025 | 2.34 Mn |
| Sep 30, 2025 | 14.52 Mn |
| Jun 30, 2025 | 2.57 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 535,162.00 |
| Jun 30, 2024 | 336,084.00 |
| Mar 31, 2024 | 343,717.00 |
| Dec 31, 2023 | 298,321.00 |
| Sep 30, 2023 | 374,200.00 |
| Jun 30, 2023 | 557,843.00 |
| Mar 31, 2023 | 497,714.00 |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 2.41 Mn |
| Mar 31, 2022 | 2.77 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 2.96 Mn |
| Jun 30, 2021 | 3.21 Mn |